Manrai Manish, George Emil, Kapoor Rajan
Department of Internal Medicine, Armed Forces Medical College, Pune, India.
Department of Internal Medicine, INHS Dhanvantari, Port Blair, Andaman & Nicobar Islands, India.
J Clin Exp Hepatol. 2021 Jan-Feb;11(1):14-20. doi: 10.1016/j.jceh.2020.06.006. Epub 2020 Jul 2.
BACKGROUND/AIMS: Hematopoietic stem cell transplantation (HSCT) is an established curative modality for various hematological malignancies and other diseases. Hepatobiliary dysfunction and subsequent sequelae constitute a common cause of morbidity and mortality in post-transplant scenario. However, data among Indian HSCT recipients is lacking.
One hundred and one HSCT recipients (37 prospective and 64 retrospective) were followed up for hepatobiliary dysfunction in the post-transplant period. The causes for hepatobiliary dysfunction were categorized as sinusoidal obstruction syndrome (SOS), formerly known as veno-occlusive disease (VOD); acute and chronic graft-versus- host disease (GVHD); drug-induced liver injury (DILI); viral infections and miscellaneous causes including bacterial, fungal and unknown causes based on clinical and laboratory evidence.
Among the 101 transplants, 56.44% ( = 57) were allogenic transplants, and 43.56% ( = 44) were autologous transplants. Hepatobiliary dysfunction was observed among 71 (70.30%) patients in first 30 days and overall, among 78 (77.23%) patients. Incidence of hepatobiliary dysfunction was higher among allogenic transplant patients compared to autologous transplants (91.23% vs. 59.09%, < 0.001). The most common cause of hepatobiliary dysfunction reported was Drug-induced liver injury (DILI). In most cases, however, hepatobiliary dysfunction was multifactorial. Sinusoidal obstruction syndrome (15.79%), acute liver GVHD (31.58%), chronic liver GVHD (33.33%) and viral infection/reactivation (26.32%) were reported only in allogenic transplant patients. 15 (14.85%) patients died of which 14 patients had hepatobiliary dysfunction, commonest cause being infections.
Our study reported a higher incidence of hepatobiliary dysfunction among Indian population post HSCT and was associated with significant mortality. In majority of the cases, the cause is multifactorial and pose a diagnostic dilemma and challenges in therapy.
背景/目的:造血干细胞移植(HSCT)是治疗各种血液系统恶性肿瘤和其他疾病的一种成熟的治愈性方法。肝胆功能障碍及其后续后遗症是移植后发病和死亡的常见原因。然而,印度造血干细胞移植受者的数据尚缺。
对101例造血干细胞移植受者(37例前瞻性和64例回顾性)在移植后进行肝胆功能障碍随访。根据临床和实验室证据,将肝胆功能障碍的原因分为窦性阻塞综合征(SOS),以前称为静脉闭塞性疾病(VOD);急性和慢性移植物抗宿主病(GVHD);药物性肝损伤(DILI);病毒感染以及包括细菌、真菌和不明原因在内的其他原因。
在101例移植中,56.44%(n = 57)为同种异体移植,43.56%(n = 44)为自体移植。在最初30天内,71例(70.30%)患者出现肝胆功能障碍,总体上,78例(77.23%)患者出现该情况。同种异体移植患者的肝胆功能障碍发生率高于自体移植患者(91.23%对59.09%,P < 0.001)。报告的肝胆功能障碍最常见原因是药物性肝损伤(DILI)。然而,在大多数情况下,肝胆功能障碍是多因素的。窦性阻塞综合征(15.79%)、急性肝GVHD(31.58%)、慢性肝GVHD(33.33%)和病毒感染/再激活(26.32%)仅在同种异体移植患者中出现。15例(14.85%)患者死亡,其中14例患者有肝胆功能障碍,最常见原因是感染。
我们的研究报告了印度造血干细胞移植后人群中肝胆功能障碍的发生率较高,且与显著的死亡率相关。在大多数情况下,原因是多因素的,给诊断带来困境并对治疗构成挑战。